Successful Clinical Cases
Lombard Medical Reports that the First Two Clinical Cases were Highly Successful
London, UK, 5 February 2007 - Lombard Medical Technologies PLC (“the Company”) announces that the first two clinical cases performed following the recommencement of European clinical procedures involving its Generation II Aorfix™ endovascular stent graft were highly successful with the stent graft deploying perfectly.
The cases were performed at the Queens Medical Centre in Nottingham and in Tromso, Norway. In both instances the clinicians performing the procedures were very pleased with both the deployment of the graft and the initial clinical results.
Further clinical cases are scheduled for this week and throughout February and beyond.
Alistair Taylor, Executive Chairman, said:
“The extensive testing undertaken prior to recommencing clinical procedures made us confident that these cases would be successful, even so we remain delighted that the device performed perfectly in both these initial procedures.”
Enquiries:
Lombard Medical Technologies PLC Tel: 01235 750 800Alistair Taylor, Executive Chairman
Brian Howlett, Chief Executive Officer
Tim Hall, Finance Director
Financial Dynamics Tel: 020 7831 3113
John Gilbert
Notes to editors
About Lombard Medical
Lombard Medical Technologies PLC is a medical devices group developing stent grafts and other medical products for use in the treatment of vascular disease. The Company’s lead product, Aorfix™, is a stent graft for the treatment of aortic aneurysms, a balloon-like enlargement of the aorta which, if untreated, may rupture and cause death. Abdominal and thoracic aortic aneurysms are the 13th largest cause of death in the US and the market is estimated to be worth approximately US$2 billion by 2010. Aorfix™ is currently being commercialised in the EU, with US clinical trials having commenced during 2006. The Company’s Polymer Coatings Division primarily develops polymer coatings for use in drug eluting stents and has a number of research collaborations developing novel products for this $6bn market.
Lombard Medical has recently successfully completed its initial public offering on AIM and was admitted to listing in December 2005, raising £23.9 million, net of expenses. The Company, based in Oxfordshire, Yorkshire and Boston, USA, employs over 90 people.
Further background on the Company can be found at www.lombardmedical.com.